RPS6KA3 and Miyoshi myopathy: Importantly, while the activation of PDPK1 is visible in clonal plasma cells of asymptomatic MM, the activation of RSK2-NTKD becomes more visible when the disease progresses to the symptomatic phase, suggesting the involvement of RSK2 activation in MM progression to the treatment-necessary disease stage [29].